Stockreport

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD [Yahoo! Finance]

REGENXBIO Inc.  (RGNX) 
Last regenxbio inc. earnings: 2/26 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.regenxbio.com
PDF Subretinal surabgene lomparvovec on track to be first gene therapy for wet AMD Topline pivotal data expected in Q4 2026 ROCKVILLE, Md. Oct. 6, 2025 /PRNewswire/ -- [Read more]